GSK2636771

• CAT Number: I001433
• CAS Number: 1372540-25-4
• Molecular Formula: C22H22F3N3O3
• Molecular Weight: 433.4
• Purity: ≥95%
• Synonyms: 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid
• Target: PI3K
• Solubility: DMSO: ≤ 10.6 mg/mL
• Storage: 3 years -20C powder
• InChI: InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)
• InChIKey: XTKLTGBKIDQGQL-UHFFFAOYSA-N
• SMILES: OC(C1=CC(N2CCOCC2)=CC3=C1N=C(C)N3CC4=C(C)C(C(F)(F)F)=CC=C4)=O

GSK2636771 (CAT: I001433) is a potent and orally bioavailable inhibitor that selectively targets PI3Kβ (phosphoinositide 3-kinase beta). It demonstrates high sensitivity to cell lines lacking the tumor suppressor gene PTEN (phosphatase and tensin homolog). By selectively inhibiting PI3Kβ, GSK2636771 interferes with the PI3K/AKT signaling pathway, which plays a crucial role in cell growth, survival, and metabolism. This selective inhibition holds therapeutic potential in cancers and diseases where aberrant PI3Kβ signaling is implicated.

Reference

[1]. Macauley D, et al. Drugs Fut, 2012, 37(6), 451.
[2]. Weigelt B, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013, 19(13), 3533-3544.